DBV Technologies Announces Plan to Implement ADS Ratio Change

Core Viewpoint - DBV Technologies plans to change the ratio of its American Depositary Shares (ADSs) to ordinary shares to regain compliance with Nasdaq's minimum bid price requirement, effective around June 3, 2024 [1][2]. Group 1: ADS Ratio Change - The current ADS Ratio of one ADS to one-half of an ordinary share will change to one ADS to one ordinary share [1]. - This change will be treated as a one-for-two reverse ADS split for ADS holders [2]. - Registered holders of certificated ADSs must surrender their ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2][3]. Group 2: Impact on Trading and Compliance - The change is expected to increase DBV's ADS trading price proportionally, although no assurance can be given that the new price will be at least double the previous price [4]. - The ADS Ratio Change will not affect the underlying ordinary shares, and no ordinary shares will be issued or cancelled [3]. Group 3: Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions [5]. - The company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT) [5]. - DBV is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for its Viaskin Peanut product [5].